BIOD News Alert Biodel Inc (BIOD) 1.36 12/25/2014 12:49:51

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Biodel Inc (BIOD) 1.36 $BIOD

PTC Therapeutics Starts Rolling NDA Filing for Translarna - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 3:10PM CST
PTC Therapeutics (PTCT) initiated the process of a rolling submission of a new drug application to the FDA for Translarna for the treatment of nonsense mutation Duchenne muscular dystrophy.
RNA: 18.76 (+0.10), SRPT: 13.88 (+0.47), PTCT: 51.66 (+0.76), BIOD: 1.36 (-0.04)

Auxilium's Xiapex Gets CHMP Nod for Peyronie's Disease - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 3:10PM CST
Auxilium Pharmaceuticals (AUXL) and partner Sobi's Xiapex is a step closer to EU approval with the CHMP giving a favorable opinion for the treatment of adult men suffering from Peyronie's disease.
ENDP: 72.10 (+0.34), CBST: 100.29 (-0.09), AUXL: 34.40 (+0.18), BIOD: 1.36 (-0.04)

Cubist's Antibiotic Zerbaxa Wins FDA Nod for cUTI and cIAI - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 3:30PM CST
Cubist's (CBST) antibiotic, Zerbaxa gained FDA approval for the treatment of adults with complicated urinary tract infections and complicated intra-abdominal infections.
ACT: 254.20 (-1.68), CBST: 100.29 (-0.09), MRK: 57.46 (+0.25), BIOD: 1.36 (-0.04)

ImmunoGen/Roche's Kadcyla Fails in Study, Shares Plunge - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 1:44PM CST
ImmunoGen (IMGN) and partner Roche's Kadcyla failed to meet the primary endpoint in a phase III study conducted in HER2-positive metastatic breast cancer patients.
LCI: 42.29 (+1.79), IMGN: 5.90 (+0.13), BIOD: 1.36 (-0.04)

PharmAthene, Inc. (PIP) in Focus: Stock Adds 7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 8:32AM CST
PharmAthene, Inc. (PIP) was a big mover last session, as the company saw its shares rise nearly 7% on the day.
IP: 54.16 (-0.38), BIOD: 1.36 (-0.04)

Dermira (DERM) Crumbles: Stock Falls by 6.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 7:59AM CST
Dermira has been witnessing a flat trend in its current year loss estimates and its share price has been falling for past 24 hours
DERM: 19.65 (+0.38), BIOD: 1.36 (-0.04)

Biodel fiscal Q4 results
Seeking Alpha - at Seeking Alpha - Thu Dec 18, 5:41AM CST

BIOD: 1.36 (-0.04)

Biodel's (BIOD) CEO Errol De Souza on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Dec 17, 8:33PM CST

BIOD: 1.36 (-0.04)

Biodel beats by $0.15
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 3:09PM CST

BIOD: 1.36 (-0.04)

Biodel Reports Fourth Quarter Fiscal Year 2014 Financial Results
Marketwired - Wed Dec 17, 3:00PM CST
Biodel Inc. (NASDAQ: BIOD) today reported financial results for the fourth fiscal quarter ended September 30, 2014.
BIOD: 1.36 (-0.04)

Salix Gains on Destocking Initiatives, Gives 2-Year Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 17, 1:12PM CST
Salix (SLXP) expects to resolve its inventory situation a year ahead of schedule and now expects a FDA response on Xifaxan 550 by May 27, 2015.
LCI: 42.29 (+1.79), SCMP: 13.75 (+0.44), SLXP: 114.92 (-1.18), BIOD: 1.36 (-0.04)

Zacks Rank #1 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 17, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
BGFV: 14.46 (-0.12), AXGN: 3.85 (+0.17), BRK.B: 151.54 (-0.21), Y: 466.26 (-0.32), BIOD: 1.36 (-0.04)

Roche (RHHBY) Presents Positive Data on Haemophilia Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 4:16PM CST
Roche (RHHBY) announced data on its pipeline candidate ACE910 at the 56th American Society of Hematology.
AGN: 210.12 (+0.95), ABBV: 66.21 (+1.86), BIOD: 1.36 (-0.04)

Biodel reports December 17
Seeking Alpha - at Seeking Alpha - Wed Dec 10, 3:20PM CST

BIOD: 1.36 (-0.04)

Biodel to Report Fourth Quarter Fiscal Year 2014 Financial Results on December 17, 2014
Marketwired - Wed Dec 10, 3:00PM CST
Biodel Inc. (NASDAQ: BIOD) will issue its fourth quarter fiscal year 2014 financial results on Wednesday, December 17, 2014. Following the release of the company's financial results, Biodel's senior management will host a conference call to discuss the results and provide an update on the company's progress.
BIOD: 1.36 (-0.04)

Cubist Shoots Up on $9.5 Billion Buyout Offer from Merck - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 09, 3:30PM CST
Merck (MRK) is set to acquire Cubist in an all-cash transaction valued at about $9.5 billion or $102 per share which will strengthen its hospital acute care portfolio.
CBST: 100.29 (-0.09), MRK: 57.46 (+0.25), BIOD: 1.36 (-0.04), HSP: 62.60 (-0.07)

Cempra (CEMP) in Focus: Stock Rises 11.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 09, 7:37AM CST
Cempra, Inc. (CEMP) was a big mover last session, as the company saw its shares rise more than 11% on the day.
LCI: 42.29 (+1.79), CEMP: 20.66 (+0.78), IG: 9.11 (-0.01), BIOD: 1.36 (-0.04)

Tetraphase Pharmaceuticals (TTPH) Jumps: Stock Up 8.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 09, 7:30AM CST
Tetraphase Pharmaceuticals, Inc. (TTPH) was a big mover last session, as the company saw its shares rise nearly 9% on the day.
LCI: 42.29 (+1.79), TTPH: 38.86 (+0.53), IG: 9.11 (-0.01), BIOD: 1.36 (-0.04)

Biodel Initiates Clinical Proof of Concept Study in Glucagon Emergency Management Program
Marketwired - Thu Dec 04, 3:19PM CST
Biodel Inc. (NASDAQ: BIOD) today announced that the company has initiated enrollment of normal human subjects in a Phase 1 clinical trial of its lyophilized glucagon formulation designed for use in a proprietary auto-reconstitution device intended for the rescue of patients with severe hypoglycemia. The combination of the formulation and the auto-reconstitution device constitutes the Glucagon Emergency Management (GEM) system, which is intended to be a more user-friendly glucagon presentation compared to emergency kits currently marketed by Eli Lilly and Novo Nordisk. The Phase 1 proof of concept study is a 6-arm cross over trial in 12 healthy volunteers in which the pharmacokinetics, pharmacodynamics, and safety of 1 mg doses of the GEM glucagon formulation, administered subcutaneously and intramuscularly, will be compared to similar injections of both marketed glucagon products.
NVO: 43.80 (+1.08), BIOD: 1.36 (-0.04)

Biodel Successfully Defends Ultra-Rapid-Acting Insulin Formulation Technology in European Patent Office Opposition Proceedings
Marketwired - Tue Nov 18, 11:26PM CST
Biodel Inc. (NASDAQ: BIOD) announced that it has successfully defended oppositions to two of its granted European patents for its ultra-rapid-acting insulin formulations, EP 2 319 500 and EP 2 106 790. A third party opposed Biodel's patents in July 2013, but the Opposition Division at the European Patent Office (EPO) recently ruled in favor of the validity of Biodel's patents. The EPO tribunal ruled that all claims of both patents are novel and inventive. Biodel therefore retains all of its patent claims as originally granted.
BIOD: 1.36 (-0.04)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

California Stone Ban Puts a Hidden Worker Toll in View

Updated Category News Views 42

Countertops are supposed to finish a kitchen, not quietly wreck the lungs of the people cutting them. Yet California's move toward prohibiting the fabrication and installation of artificial stone containing more than 1% crystalline silica puts an ugly, long-running occupational-health problem in plain sight. This is not a story that calls for chest-thumping market talk....

Continue Reading
Water Damage Coverage Has More Traps Than Homeowners Think

Updated Category News Views 29

A wet basement does not care one bit whether the water arrived dramatically or dripped in for months. That ugly distinction, though, can decide whether a homeowner has an insurance claim or a repair bill that lands with a thud. Kathy Thurmond-Edwards, an insurance expert in Memphis, Tennessee, lays out the dividing lines plainly: sudden pipe failures may be treated very...

Continue Reading
ACP's 1-for-4 Split Raises Price, Not Investor Value Yet

Updated Category News Views 68

Four ACP shares are about to become one, and the calculator crowd is liable to make a mountain out of a bookkeeping move. abrdn Income Credit Strategies Fund will execute a 1-for-4 reverse split before the opening bell on December 7, 2026. The quoted share price should rise by roughly four times, but the economic stake held by an investor does not magically get bigger...

Continue Reading
Surf City Seasons Put Vacation Rental Timing in Focus

Updated Category News Views 28

Summer’s Calendar Does the Talking School bells, not seagulls, appear to set the pace for Surf City’s rental market. Chris Rackley’s seasonal guide makes a pretty grounded point: the “best” time to visit Surf City, North Carolina, is not some universal magic week on a postcard. It depends on whether a traveler needs peak beach weather, wants elbow room, or...

Continue Reading
Home Nursing Plans Need Clarity Before the Next Crisis

Updated Category News Views 71

A medication change scribbled on a loose sheet can become a very long night. That is the unglamorous truth behind the discussion from Michael and Marsha Reda of Aurora Home Care in Williamsville, New York: long-term home nursing care depends on a plan people can actually follow when the household is tired, worried, and juggling too much. Their perspective, featured by...

Continue Reading
Cash Flow Discipline Is Where Business Growth Gets Real

Updated Category News Views 73

A full order book can still leave a company gasping at payroll. That is the unglamorous point behind the Nov. 20, 2026, HelloNation piece featuring Kimberly Furrh of Furrh & Associates PC in Lawton, Oklahoma. Owners love to talk about sales because sales are visible, flattering and easy to celebrate. Cash is less theatrical. It is also the thing that keeps the lights on...

Continue Reading
Tessera Delisting Leaves HLSQ in a Tougher Market Ahead

Updated Category News Views 116

November delivered a nasty little truth serum for Tessera Defense and Homeland Security: exchange status is not a cosmetic detail when the stock’s selling price has collapsed. On November 10, NYSE Regulation suspended trading in the company’s common shares on NYSE American and began delisting proceedings. By November 17, Tessera had a chance to request review by the...

Continue Reading
Rock Gate Buys Aviation Niche Player Blast Deflectors

Updated Category News Views 110

Jet exhaust is not glamorous, but somebody has to keep it from battering everything nearby. Rock Gate Partners’ acquisition of Blast Deflectors, Inc. puts money behind one of those stubbornly unsexy industrial niches where engineering credibility matters far more than a flashy sales pitch. The transaction closed October 16, 2026, and Northborne Partners announced...

Continue Reading
Rosalind Franklin University’s $23.8M Scholarship Win

Updated Category News Views 80

Twenty-three million dollars can disappear fast in graduate health education, which is exactly why Rosalind Franklin University’s campaign result deserves more than a polite round of applause. The university’s five-year Empowering Scholars effort closed in June 2026 with $23,836,272 raised, clearing its $20 million target by roughly 19%. In a world where institutions...

Continue Reading
Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 61

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading

Top 5 Most Recently Viewed Articles

Thompson Thrift Secures Over $255 Million in New Funding

Updated Category News Views 303

Thompson Thrift Closes Major Funding Round for Multifamily Developments Thompson Thrift, a well-known real estate company, recently announced a significant achievement in closing its 2025 multifamily development fund. This limited partnership offering successfully raised over $255 million in capital commitments, exceeding its original target of $230 million. The funds aim...

Continue Reading
Buyglobal's Summer Sale Offers Outdoor Essentials and Deals

Updated Category News Views 25

Buyglobal's Summer Event: A Sunny Boost for Backyard Living Summer's rolling in, and Buyglobal is gearing up to help you transform those backyard spaces into your very own oasis. This ain't your average sale event—this is Buyglobal jumping headfirst into the season with a curated lineup that's all about making the most of the outdoors. They rolled out their...

Continue Reading
Tony Fadell Champions Plumerai's Tiny AI for Smart Homes

Updated Category News Views 201

Transforming Smart Home Security with Tiny AI In the realm of innovative technology, Tony Fadell, co-creator of the iPod and Nest founder, recognizes the groundbreaking work Plumerai is doing in the field of artificial intelligence. Their emphasis on Tiny AI technology is heralded as a pivotal shift that aims to democratize AI for everyday use, particularly in smart home...

Continue Reading
Glenn Pushis Takes Action: Sells $172K in Steel Dynamics Shares

Updated Category News Views 183

Understanding Insider Actions at Steel Dynamics A notable insider transaction has come to light involving Glenn Pushis, the Senior Vice President at Steel Dynamics (NASDAQ: STLD). This transaction was detailed through an SEC filing that disclosed a significant sell-off of shares worth $172,043. Details of the Sell-Transaction According to the Form 4 filing submitted to...

Continue Reading
SCF Partners Strengthens Market Position with New Acquisition

Updated Category News Views 228

SCF Partners' Strategic Acquisition of Newpark Fluids Systems SCF Partners is making waves with its recent acquisition of Newpark Fluids Systems, a well-respected name in the oil, gas, and geothermal fluids industry. This strategic decision underscores SCF's dedication to broadening its service offerings and expanding its market presence. Newpark Fluids Systems has built...

Continue Reading